JPMorgan downgraded Precigen to Underweight from Neutral without a price target. With a growing financing overhang, Precigen will underperform its peers, the analyst tells investors in a research note. The firm acknowledges the unmet needs in Precigen’s lead indication, and the benefits PRGN-2012 demonstrated in recurrent respiratory papillomas, but is cautious on its path forward.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
